Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to -$1.8 million.

  • Arcutis Biotherapeutics' Cash from Operations rose 9494.35% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.6 million, marking a year-over-year increase of 8058.02%. This contributed to the annual value of -$112.2 million for FY2024, which is 5460.24% up from last year.
  • Arcutis Biotherapeutics' Cash from Operations amounted to -$1.8 million in Q3 2025, which was up 9494.35% from $324000.0 recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Cash from Operations ranged from a high of $324000.0 in Q2 2025 and a low of -$80.3 million during Q1 2023
  • Its 5-year average for Cash from Operations is -$43.3 million, with a median of -$45.1 million in 2024.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Cash from Operations tumbled by 11990.96% in 2021 and then skyrocketed by 10071.81% in 2025.
  • Arcutis Biotherapeutics' Cash from Operations (Quarter) stood at -$51.7 million in 2021, then crashed by 37.43% to -$71.1 million in 2022, then increased by 20.86% to -$56.2 million in 2023, then soared by 98.67% to -$748000.0 in 2024, then tumbled by 134.49% to -$1.8 million in 2025.
  • Its last three reported values are -$1.8 million in Q3 2025, $324000.0 for Q2 2025, and -$30.4 million during Q1 2025.